Envisagenics, an AI-driven biotechnology company revolutionizing RNA splicing research and therapeutics, has appointed Sudhir Rao, M.S., MBA as Chief Business Officer (CBO) to expand and strengthen its leadership team. Mr. Rao’s extensive leadership in biopharma R&D, business development, alliance management, and strategy will drive Envisagenics’ position as a leader in RNA splicing therapeutics and the overall growth of the company.
Sudhir Rao brings over 30 years of experience in the life sciences industry, with the last 15 years in business development, spanning both buy side and sell side positions in large pharma and small biotech. He has successfully led and executed numerous high-impact partnerships across oncology, CNS, GI, and immunology therapeutic areas. He has held business positions of increasing responsibility in multiple organizations including most recently being Senior Vice President/Head of Business Development at Expansion Therapeutics, Vice President of Business Development at Genocea Biosciences and Transactions Lead at Takeda Pharmaceuticals.
“We are delighted to welcome Sudhir to Envisagenics,” said Maria Luisa Pineda, Ph.D., Envisagenics‘ co-founder and CEO. “His extensive experience across scientific and business disciplines, combined with his passion for advancing innovative science, will be instrumental for our mission to harness the therapeutic potential of RNA splicing. Sudhir’s leadership will help us expand partnerships, bring novel therapies to market, and continue our growth trajectory.”
“I am excited to join Envisagenics at this pivotal stage in the company’s development,” said Sudhir Rao. “The company’s cutting-edge, AI-driven SpliceCore® platform identifies novel targets, paving the way for innovative treatments in oncology, neurodegenerative diseases, and beyond. I look forward to collaborating with the talented team to execute impactful partnerships, expand our relationships with investors and enable the development of groundbreaking therapies for patients.”
